ImmunityBio, Inc. (NASDAQ:IBRX) Sees Large Increase in Short Interest

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of a large increase in short interest in February. As of February 29th, there was short interest totalling 51,550,000 shares, an increase of 9.4% from the February 14th total of 47,140,000 shares. Approximately 39.4% of the shares of the company are short sold. Based on an average trading volume of 4,230,000 shares, the short-interest ratio is presently 12.2 days.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. increased its position in ImmunityBio by 15.9% in the fourth quarter. American International Group Inc. now owns 65,902 shares of the company's stock worth $331,000 after buying an additional 9,043 shares during the period. Virtu Financial LLC acquired a new position in shares of ImmunityBio during the fourth quarter valued at $304,000. Price T Rowe Associates Inc. MD increased its holdings in shares of ImmunityBio by 8.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 119,346 shares of the company's stock valued at $601,000 after purchasing an additional 8,834 shares during the period. Legal & General Group Plc increased its holdings in shares of ImmunityBio by 2.2% during the fourth quarter. Legal & General Group Plc now owns 120,529 shares of the company's stock valued at $605,000 after purchasing an additional 2,566 shares during the period. Finally, Barclays PLC increased its holdings in shares of ImmunityBio by 980.7% during the fourth quarter. Barclays PLC now owns 479,545 shares of the company's stock valued at $2,406,000 after purchasing an additional 435,172 shares during the period. 8.60% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Stock Performance

Shares of IBRX stock traded up $0.10 on Monday, hitting $5.23. 3,178,737 shares of the stock traded hands, compared to its average volume of 3,910,899. ImmunityBio has a 1-year low of $1.25 and a 1-year high of $6.93. The company's fifty day moving average is $4.31 and its 200 day moving average is $3.39.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.